Allegro: Making its mark on lung cancer

By Erin McCallister Senior Writer

Current practices for diagnosing lung cancer are highly invasive, require multiple examinations and as a result may take up to 12 months to deliver a definitive answer, often after the cancer has progressed beyond a curative stage. Allegro Diagnostics Inc.is developing a noninvasive biomarker-based test that it hopes will provide patients and clinicians with a quicker diagnosis. This could translate into improved survival for non-small cell lung cancer patients...